$RVT

Royce Small-Cap Trust (NYSE: RVT) as of May 31, 2025 - Royce Value Trust (NYSE:RVT)

Oldest and largest small-cap closed-end fund Average weekly trading volume of approximately 1,016,636 shares Fund's adviser has more than 50 years of small- and micro-cap investment experience

Original reporting
Benzinga · PRNewswire
Published Jun 26, 2025, 5:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 26, 2025, 6:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$RVT
Neutral
medium confidence
Mentioned
$RVT
AlphAI data visualization · based on Benzinga
Decision brief

The 30-second read

$RVTNeutralLow
01

Why it matters

The information underscores the fund's stability but offers limited insights into recent performance or market dynamics.

02

Market read

The news is primarily relevant to investors interested in small-cap funds and those seeking stable, liquid investment options within this sector.

03

What to watch

Potential impacts of macroeconomic changes, interest rate fluctuations, and small-cap sector shifts are not detailed but could influence future performance.

Timing: Long-term

Background

The article provides an update on Royce Small-Cap Trust as of May 31, 2025, emphasizing its historical significance, trading volume, and management experience.

Company-level read

Ticker impact

$RVTNeutralMedium confidence
Context

The news pertains directly to Royce Small-Cap Trust (NYSE: RVT), providing updated financial and operational data as of May 31, 2025.

Expected impact

Minimal short-term price movement expected; long-term impact depends on broader market conditions and fund performance.

Evidence & confidence

While the fund's size and management experience are positive, the lack of recent performance data and market context limits the certainty of price impact predictions.

Market effects

The fund's focus on small-cap investments may influence sector-specific liquidity and investor interest in small-cap equities.

Limited regional impact; primarily relevant to U.S. small-cap investment landscape.

Minimal; the fund's operations are primarily within the U.S. market.

Counterpoint

Some investors may view the fund's size and age as potential drawbacks if growth prospects diminish or if market conditions favor newer, more agile funds.

Key entities

  • Royce Small-Cap Trust

    A small-cap closed-end investment fund with a long-standing history and significant trading volume.

  • Royce Value Trust

    The parent or related investment vehicle, emphasizing value-oriented small-cap investments.

Related articles

$GISMed

General Mills Announces Dana McNabb As CEO

General Mills' board elected Dana McNabb, current COO, as CEO effective January 2027, succeeding Jeff Harmening, who will become executive chair. McNabb, with 27 years at the company, has led key operating segments and functions. She aims to drive profitable growth through digital demand and supply chain modernization, building on Harmening's foundation.

$GISMed

General Mills Names First Woman CEO

General Mills has named Dana McNabb as its next CEO, the first woman to lead the company. McNabb, currently COO, will take over on January 1. Current CEO Jeff Harmening will become executive chairman. The board unanimously approved the change.

$HPEMedAI 8/10

HPE Networking chief links $1.2B Vultr neocloud win to ‘revenue synergy’ opportunity

Hewlett Packard Enterprise (HPE) secured a $1.2B deal with Vultr for its AMD Helios AI Rack system, highlighting revenue synergy opportunities. The deal involves deploying HPE's AI Rack in Vultr's U.S. data centers to support AI workloads. HPE's executive Rami Rahim stated this opens a new networking market, with Helios representing a billion-dollar opportunity over two years, and networking tray orders already exceeding $200M.

$LLYMedAI 8/10

Retatrutide Yields Significant Weight Loss in T2D

Eli Lilly's phase 3 TRIUMPH-2 study shows retatrutide, a triple hormonal agonist, achieved significant weight loss (up to 20.8%) and glycemic improvements in adults with type 2 diabetes (T2D) and obesity. The study, presented at EASD 2026, involved 1152 participants and showed retatrutide's efficacy estimand exceeded 20% weight reduction, a threshold not previously reached in T2D patients.

$BAMMedAI 9/10

U.S. – Korea Framework Advances Deployment of Westinghouse Nuclear Technology in the United States

The U.S. and Korea agreed on a framework committing up to $120B in Korean investment for constructing eight nuclear reactors in the U.S., including six Westinghouse AP1000 reactors and two Korean APR1400 reactors. The deal includes a 5-10% equity investment in Westinghouse by Korea. Brookfield Asset Management and Cameco are partners in the project, which aims to expand U.S. nuclear capacity to meet growing energy demand.